Related Pages Myeloproliferative Disorders Home Page 1 NCI's gateway for information about myeloproliferative disorders. Search for Clinical Trials 2 NCI's PDQ® Cancer Clinical Trials Registry.

1.  Azacitidine Improves Survival in Myelodysplastic Syndromes ³
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.

2.  Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia ⁴
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.

3.  Lenalidomide Reduces Need for Blood Transfusions in Myelodysplastic Syndrome ⁵
(Posted: 05/15/2005) - Lenalidomide (Revlimid™) reduced the need for blood transfusions in some patients with myelodysplastic syndrome (MDS), according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.